Publication:
Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect

Simple item page
dc.contributor.authorYILMAZ, BETÜL
dc.contributor.authorsKaplan, Gulce Sari; Torcun, Ceyda Corek; Grune, Tilman; Ozer, Nesrin Kartal; Karademir, Betul
dc.date.accessioned2022-03-10T15:25:24Z
dc.date.available2022-03-10T15:25:24Z
dc.date.issued2017
dc.description.abstractProteasomal system plays an important role in protein turnover, which is essential for homeostasis of cells. Besides degradation of oxidized proteins, it is involved in the regulation of many different signaling pathways. These pathways include mainly cell differentiation, proliferation, apoptosis, transcriptional activation and angiogenesis. Thus, proteasomal system is a crucial target for treatment of several diseases including neurodegenerative diseases, cystic fibrosis, atherosclerosis, autoimmune diseases, diabetes and cancer. Over the last fifteen years, proteasome inhibitors have been tested to highlight their mechanisms of action and used in the clinic to treat different types of cancer. Proteasome inhibitors are mainly used in combinational therapy along with classical chemo-radiotherapy. Several studies have proved their significant effects but serious side effects such as peripheral neuropathy, limits their use in required effective doses. Recent studies focus on peripheral neuropathy as the primary side effect of proteasome inhibitors. Therefore, it is important to delineate the underlying mechanisms of peripheral neuropathy and develop new inhibitors according to obtained data. This review will detail the role of proteasome inhibition in cancer therapy and development of peripheral neuropathy as a side effect. Additionally, new approaches to prevent treatment limiting side effects will be discussed in order to help researchers in developing effective strategies to overcome side effects of proteasome inhibitors.
dc.identifier.doi10.1016/j.freeradbiomed.2016.12.007
dc.identifier.eissn1873-4596
dc.identifier.issn0891-5849
dc.identifier.pubmed27940347
dc.identifier.urihttps://hdl.handle.net/11424/220233
dc.identifier.wosWOS:000393014600001
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofFREE RADICAL BIOLOGY AND MEDICINE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectProteasome
dc.subjectBortezomib
dc.subjectCarfilzomib
dc.subjectChemotherapy
dc.subjectNeuropathy
dc.subjectNF-KAPPA-B
dc.subjectUBIQUITIN-INDEPENDENT DEGRADATION
dc.subjectVIVO SYNERGISTIC CYTOTOXICITY
dc.subjectDIAGNOSED MULTIPLE-MYELOMA
dc.subjectBORTEZOMIB PLUS MELPHALAN
dc.subjectIN-VIVO
dc.subjectINDUCED APOPTOSIS
dc.subjectBETA-CATENIN
dc.subjectRETINOBLASTOMA PROTEIN
dc.subjectSINGLE-AGENT
dc.titleProteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect
dc.typereview
dspace.entity.typePublication
local.avesis.id373f0d1c-9265-4d43-9c44-9cb79e8b934a
local.import.packageSS5
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages13
local.journal.quartileQ1
oaire.citation.endPage13
oaire.citation.startPage1
oaire.citation.titleFREE RADICAL BIOLOGY AND MEDICINE
oaire.citation.volume103
relation.isAuthorOfPublication81633a07-e5fb-4760-b3ef-bf0878d87827
relation.isAuthorOfPublication.latestForDiscovery81633a07-e5fb-4760-b3ef-bf0878d87827

Files

Collections

Research Outputs